XHKG2190
Market cap451mUSD
Dec 27, Last price
11.16HKD
1D
-1.24%
1Q
-11.43%
IPO
-80.02%
Name
Zylox-Tonbridge Medical Technology Co Ltd
Chart & Performance
P/E
—
P/S
6.25
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
528m
+57.97%
Net income
-79m
L-34.61%
CFO
98m
P
Earnings
Jun 06, 2025
Profile
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices China and internationally. It primarily offers ThromBite Clot Retriever Device, which is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke; Balloon Guiding Catheter; Cylone Aspiration Catheter; ZENFLEX Pro Peripheral Drug-eluting Stent System for complex lesions and restenotic symptomatic lesions; ZENFlex Peripheral Stent System to deliver a self-expanding stent to the iliac artery, superficial femoral arteries, and/or proximal popliteal arteries through a 6F delivery system; and drug-coated percutaneous transluminal angioplasty (PTA) Balloon Catheters that are indicated for PTA of stenosis or occlusion lesions in iliac, femoral, or popliteal arteries. The company also provides Ton-Bridge extra soft coils for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities, such as arteriovenous malformations and arteriovenous fistulae; microcatheter for coiling; distal access catheter; glycine micro catheter for professional physician to selectively inject or input control medium and/or embolic materials, and/or appropriate devices; Intracranial PTA balloon catheter; vascular snare; and snare retrieval kit for IVC filter. Zylox-Tonbridge Medical Technology Co., Ltd. was incorporated in 2012 and is headquartered in Zhejiang, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 527,754 57.97% | 334,090 87.78% | 177,912 543.89% | ||
Cost of revenue | 681,694 | 564,356 | 409,999 | ||
Unusual Expense (Income) | |||||
NOPBT | (153,940) | (230,266) | (232,087) | ||
NOPBT Margin | |||||
Operating Taxes | 6,852 | (13,638) | |||
Tax Rate | |||||
NOPAT | (153,940) | (237,118) | (218,449) | ||
Net income | (78,734) -34.61% | (120,407) -35.28% | (186,051) 87.02% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (53,801) | (24,644) | 2,959,085 | ||
BB yield | 1.32% | 0.58% | -42.56% | ||
| Debt | |||||
Debt current | 54,018 | 6,543 | 2,896 | ||
Long-term debt | 7,736 | 21,461 | 15,914 | ||
Deferred revenue | 8,674 | ||||
Other long-term liabilities | |||||
Net debt | (2,515,311) | (2,009,734) | (2,910,064) | ||
| Cash flow | |||||
Cash from operating activities | 98,440 | (91,323) | (116,206) | ||
CAPEX | (190,919) | (145,281) | (89,595) | ||
Cash from investing activities | (206,241) | (95,045) | (1,328,351) | ||
Cash from financing activities | (11,462) | (30,257) | 2,809,823 | ||
FCF | (298,474) | (477,597) | (148,439) | ||
| Balance | |||||
Cash | 1,510,869 | 1,860,671 | 2,928,874 | ||
Long term investments | 1,066,196 | 177,067 | |||
Excess cash | 2,550,677 | 2,021,034 | 2,919,978 | ||
Stockholders' equity | (149,506) | 857,913 | 883,790 | ||
Invested Capital | 3,261,442 | 2,241,309 | 2,265,821 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 328,711 | 330,388 | 294,595 | ||
Price | 12.44 -3.12% | 12.84 -45.59% | 23.60 | ||
Market cap | 4,089,165 -3.61% | 4,242,182 -38.98% | 6,952,442 | ||
EV | 1,573,854 | 2,232,448 | 4,042,378 | ||
EBITDA | (118,060) | (203,998) | (218,705) | ||
EV/EBITDA | |||||
Interest | 1,251 | 722 | 307 | ||
Interest/NOPBT | |||||